8:18 AM
 | 
Apr 13, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

China FDA approves IND for Canbridge's GBM candidate

Canbridge Life Sciences Ltd. (Beijing, China) said China FDA approved an IND to begin a Phase II/III trial of asunercept (APG101, CAN-008) to treat glioblastoma multiforme (GBM).

A spokesperson told BioCentury...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >